_edited.png)
Aurobindo Pharma Shares Fall After USFDA Flags Eugia Facility With OAI Status
Aurobindo Pharma shares declined more than 5% after the USFDA classified Eugia Pharma Specialities' Unit III manufacturing facility in Telangana as Official Action Indicated following a recent inspection. The regulatory status restricts approvals for new drug applications from the facility until the observations are resolved, impacting investor sentiment despite no immediate operational impact.
By Finblage Editorial Desk
2:50 pm
15 June 2026
Shares of Aurobindo Pharma Ltd came under pressure on Monday after the US Food and Drug Administration (USFDA) classified Eugia Pharma Specialities' Unit III manufacturing facility in Telangana as "Official Action Indicated" (OAI). The stock fell 5.42% to ₹1,393 on the NSE, making it one of the worst performers in both the Nifty Pharma index and the BSE Mid-Cap index.
Eugia Pharma Specialities, a wholly owned subsidiary of Aurobindo Pharma, received the classification following a USFDA inspection conducted between January 27 and February 6, 2026. The inspection concluded with 11 observations, and the company was informed of the OAI status on June 12, 2026.
An OAI classification indicates that the USFDA has identified significant compliance issues that may warrant regulatory or administrative action. While the facility is permitted to continue manufacturing and supplying products that have already received regulatory approval, it will not be eligible to obtain approvals for new drug applications until the identified concerns are adequately addressed.
The regulatory action weighed on investor sentiment, even though Aurobindo Pharma stated that the classification is not expected to have any impact on its existing operations or financial performance.
The development also affected the broader pharmaceutical sector, with the Nifty Pharma index declining 0.61% during an otherwise positive market session, making it the only major sectoral index trading in negative territory.
The decline comes shortly after Aurobindo Pharma announced its entry into the biologics contract manufacturing segment through the launch of TheraNym, a dedicated biologics contract manufacturing organization. However, market attention remained focused on the USFDA's regulatory observations and the timeline for corrective actions at the Eugia facility.
Sources & Disclaimer
This article is compiled from publicly available information, including company disclosures, stock exchange filings, regulatory announcements, and reports from global and domestic financial publications. The content has been editorially reviewed and enhanced by the Finblage Editorial Desk for clarity and investor awareness purposes only.
All information provided on Finblage is strictly for educational and informational use and should not be considered as financial, investment, legal, or professional advice. Readers are advised to conduct their own independent research and consult a certified financial advisor before making any investment decisions. Finblage shall not be held responsible for any losses arising from the use of information published on this website.
Premium Edition
Insight
India's 2026 Monsoon : When the Rain Becomes a Risk
After two consecutive years of above-normal rainfall, India faces a significantly weaker 2026 southwest monsoon, with meteorological agencies forecasting rainfall at around 90% of the Long Period Average amid rising El Niño risks. A deficient monsoon could weigh on agricultural output, rural incomes, food inflation, and overall economic growth, while creating sector-specific winners and losers across the equity market.
5 July 2026
